DESONATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DESONATE (DESONATE).
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
| Metabolism | Desonide is primarily metabolized in the liver via oxidative and conjugative pathways. The exact enzymes involved are not well characterized. |
| Excretion | Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%). |
| Half-life | Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing. |
| Protein binding | Desonide is 78-85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<5% in healthy skin) but increases with occlusion or damaged skin; oral bioavailability is not clinically relevant as desonide is not administered orally. |
| Onset of Action | Topical: Improvement in pruritus and erythema typically within 24-48 hours. |
| Duration of Action | Topical: Duration of effect is approximately 12 hours with twice-daily application; continuous use beyond 2 weeks should be avoided due to potential for adrenal suppression. |
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment guidelines for hepatic impairment; use with caution. |
| Pediatric use | Apply 0.05% cream, lotion, or ointment topically to affected area once or twice daily for up to 2 weeks; use smallest amount for shortest duration. |
| Geriatric use | Apply 0.05% cream, lotion, or ointment topically to affected area twice daily; use caution due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DESONATE (DESONATE).
| Breastfeeding | It is not known whether topical desonide is excreted in human milk. Systemic corticosteroids are excreted in breast milk in small amounts (M/P ratio not reported for desonide; for prednisolone M/P ~0.2). Because many drugs are excreted in human milk, caution should be exercised when desonide is administered to a nursing woman. Use on limited areas, minimal duration, and avoid application to breast area when nursing infant may contact the site. |
| Teratogenic Risk | Corticosteroids, including desonide, are classified as Pregnancy Category C. In animal reproduction studies, corticosteroids have been shown to be teratogenic (cleft palate, skeletal abnormalities) at doses equivalent to human doses. There are no adequate and well-controlled studies in pregnant women. First trimester: risk of oral clefts (odds ratio ~3.4) based on epidemiological data with systemic corticosteroids. Second/third trimester: potential for fetal adrenal suppression, intrauterine growth restriction, and low birth weight. Topical application minimizes systemic exposure, but risk increases with extensive use, occlusive dressings, or prolonged treatment. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to desonide or any component of the formulation","Untreated bacterial, fungal, or viral skin infections"]
| Precautions | ["Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression.","Use with caution in patients with skin infections; may mask or worsen infections.","Avoid prolonged use on face, intertriginous areas, or under occlusive dressings.","Potential growth retardation in pediatric patients.","Local adverse reactions including atrophy, striae, and telangiectasia."] |
Loading safety data…
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother with prolonged or extensive use (cosyntropin stimulation test if symptoms). Monitor infant for growth parameters, signs of adrenal suppression (e.g., poor feeding, lethargy) if maternal use is extensive or prolonged. Fetal ultrasound for growth assessment if used in second/third trimester for extended periods. |
| Fertility Effects | No human studies on fertility effects of topical desonide. In animal studies, systemic corticosteroids may impair fertility (e.g., altered estrous cycle, reduced spermatogenesis) at high doses. Topical application with minimal systemic absorption likely has negligible impact on fertility, but data are lacking. |